U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21040LBL.PDF

Norgestimate is a steroidal progestin of the 19-nortestosterone group that is used in combination with ethinylestradiol as an oral contraceptive and for treatment of acne. and in combination with estradiol in menopausal hormone replacement therapy. Norgestimate shows high selectivity for the progesterone receptor and low androgenic activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.4 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ORTHO CYCLEN-21

Approved Use

Norgestimate and Ethinyl Estradiol lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Launch Date

6.3089279E11
Primary
ORTHO CYCLEN-21

Approved Use

Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. Norgestimate and Ethinyl Estradiol Tablets USP, are indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Norgestimate and Ethinyl Estradiol Tablets USP should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control.

Launch Date

6.3089279E11
Palliative
ORTHO-PREFEST

Approved Use

ORTHO-PREFEST™ therapy is indicated in women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with the menopause, treatment of vulvar and vaginal atrophy, prevention of osteoporosis.

Launch Date

9.4046401E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
515 pg/mL
0.09 mg single, oral
dose: 0.09 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
779.2 pg/mL
180 μg single, oral
dose: 180 μg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
643 pg/mL
0.09 mg 1 times / day multiple, oral
dose: 0.09 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2146 pg × h/mL
0.09 mg single, oral
dose: 0.09 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9522.7 pg × h/mL
180 μg single, oral
dose: 180 μg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
5322 pg × h/mL
0.09 mg 1 times / day multiple, oral
dose: 0.09 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37 h
0.09 mg single, oral
dose: 0.09 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30.4 h
180 μg single, oral
dose: 180 μg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
0.09 mg single, oral
dose: 0.09 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ESTRADIOL
NORGESTIMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (4 patients)
Abdominal pain (15 patients)
Nausea (27 patients)
Sinusitis (8 patients)
URTI (8 patients)
Breast pain (13 patients)
Dysmenorrhea (13 patients)
Headache (38 patients)
Sources:
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (4 patients)
Abdominal pain (4 patients)
Nausea (20 patients)
URTI (16 patients)
Breast pain (4 patients)
Dysmenorrhea (12 patients)
Headache (27 patients)
Sources:
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (11 patient)
Abdominal pain (13 patients)
Nausea (21 patient)
Sinusitis (6 patients)
URTI (13 patients)
Breast pain (9 patients)
Dysmenorrhea (15 patients)
Headache (26 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Breast pain 13 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Dysmenorrhea 13 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Abdominal pain 15 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Nausea 27 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Headache 38 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Vomiting 4 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Sinusitis 8 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
URTI 8 patients
215 ug 1 times / day multiple, oral (median)
Dose: 215 ug, 1 times / day
Route: oral
Route: multiple
Dose: 215 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Dysmenorrhea 12 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
URTI 16 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Nausea 20 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Headache 27 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Abdominal pain 4 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Breast pain 4 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Vomiting 4 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 49
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 49
Sources:
Vomiting 11 patient
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Abdominal pain 13 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
URTI 13 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Dysmenorrhea 15 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Nausea 21 patient
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Headache 26 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Sinusitis 6 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Breast pain 9 patients
305 ug 1 times / day multiple, oral (mean)
Dose: 305 ug, 1 times / day
Route: oral
Route: multiple
Dose: 305 ug, 1 times / day
Co-administed with::
ethinyl estradiol(35 ug)
Sources:
healthy, 18 - 40 years
n = 48
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 48
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
yes (co-administration study)
Comment: Simultaneous and staggered EE/norgestimate and lomitapide administration resulted in an approximately 1.3-fold increase in lomitapide exposure
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
PubMed

PubMed

TitleDatePubMed
Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
1992
Cerebral thrombosis and oral contraceptives. A case-control study.
1998 May
Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties.
2003 Feb
The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.
2003 Mar
Clinical profile of contraceptive progestins.
2004 Sep
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
2005 Dec
Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2).
2005 Nov
Patents

Sample Use Guides

Norgestimate and Ethinyl Estradiol Tablets are dispensed in a blister pack . Norgestimate and Ethinyl Estradiol Tablets USP may be started using either a Day 1 start or a Sunday start. For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.
Route of Administration: Oral
In Vitro Use Guide
The relative affinities of the steroids for cytosolic progestin receptors were assessed by their ability to displace 3H-R5020, a highly specific synthetic progestin, from rabbit uterine receptors. Immature female rabbits were primed with 17 beta-estradiol (5 mcg sc) daily for five days and then sacrificed on day six. The excised uteri were washed and homogenized in ice cold Tris-EDTA buffer (1:5 w/v; pH 7.4). The homogenate was centrifuged at 105,000 x g at 4°C for one hour and the supernatant was used as the cytosolic progestin receptor preparation. Aliquots of the cytosol preparation were incubated with 0.4 nM 3H-R5020 (86.2 Ci/mmole; New England Nuclear) and unlabelled test steroids in Tris-EDTA buffer for 5 hours at 4°C. After incubation, free 3H-R5020 was extracted with dextran-coated charcoal from the bound ligand, and the amount of 3H-R5020 bound to the receptor was determined by liquid scintillation spectrometry. The concentration of the test progestin corresponding to 50% inhibition of total 3H-R5020 binding (IC50) was used as the measure of binding affinity for the progestin receptor. For norgestimate IC50 was found to be 3.4 nM.
Substance Class Mixture
Created
by admin
on Sat Dec 16 18:10:53 UTC 2023
Edited
by admin
on Sat Dec 16 18:10:53 UTC 2023
Record UNII
C291HFX4DY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORGESTIMATE
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PREFEST COMPONENT NORGESTIMATE
Common Name English
NORGESTIMATE [USP-RS]
Common Name English
NORGESTIMATE COMPONENT OF TRI-PREVIFEM
Common Name English
ORF 10131
Code English
TRI-PREVIFEM COMPONENT NORGESTIMATE
Common Name English
TRI-SPRINTEC COMPONENT NORGESTIMATE
Common Name English
NORGESTIMATE COMPONENT OF ORTHO TRI-CYCLEN
Common Name English
NORGESTIMATE COMPONENT OF SPRINTEC
Common Name English
18,19-DINOR-17-PREGN-4-EN-20-YN-3-ONE, 17-(ACETYLOXY)-13-ETHYL-, OXIME, (17.ALPHA.)-(+)-
Common Name English
NORGESTIMATE [ORANGE BOOK]
Common Name English
NORGESTIMATE COMPONENT OF TRI-SPRINTEC
Common Name English
MIXTURE OF NORGESTIMATE (E)-AND (Z)-ISOMERS HAVING A RATIO OF (E)-TO (Z)-ISOMER BETWEEN 1.27 AND 1.78
Common Name English
NORGESTIMATE [VANDF]
Common Name English
Norgestimate [WHO-DD]
Common Name English
NORGESTIMATE [USP MONOGRAPH]
Common Name English
PREVIFEM COMPONENT NORGESTIMATE
Common Name English
NORGESTIMATE [MI]
Common Name English
NSC-759159
Code English
NORGESTIMATE COMPONENT OF TRI LO SPRINTEC
Common Name English
ORF-10131
Code English
NORGESTIMATE [MART.]
Common Name English
NORGESTIMATE [EP MONOGRAPH]
Common Name English
NORGESTIMATE COMPONENT OF PREVIFEM
Common Name English
RWJ-10131
Code English
(+)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE OXIME ACETATE (ESTER)
Common Name English
NORGESTIMATE [USAN]
Common Name English
TRI LO SPRINTEC COMPONENT NORGESTIMATE
Common Name English
norgestimate [INN]
Common Name English
NORGESTIMATE COMPONENT OF PREFEST
Common Name English
ORTHO TRI-CYCLEN COMPONENT NORGESTIMATE
Common Name English
SPRINTEC COMPONENT NORGESTIMATE
Common Name English
RWJ 10131
Code English
Classification Tree Code System Code
WHO-VATC QG03AA11
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
NDF-RT N0000011301
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
NDF-RT N0000175602
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
WHO-ATC G03FA13
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
WHO-VATC QG03FA13
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
NCI_THESAURUS C776
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
LIVERTOX 698
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
WHO-ATC G03AA11
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C66245
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
IUPHAR
7091
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
WIKIPEDIA
NORGESTIMATE
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
RXCUI
31994
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY RxNorm
CAS
35189-28-7
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
EVMPD
SUB09369MIG
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID1046922
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
PUBCHEM
37083
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
MERCK INDEX
m8062
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY Merck Index
CHEBI
50815
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
DRUG CENTRAL
1968
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
RS_ITEM_NUM
1471914
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
SMS_ID
100000083617
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
NSC
759159
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
MESH
C017576
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
INN
3942
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
HSDB
7898
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
FDA UNII
C291HFX4DY
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
DAILYMED
C291HFX4DY
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
DRUG BANK
DB00957
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL1200934
Created by admin on Sat Dec 16 18:10:54 UTC 2023 , Edited by admin on Sat Dec 16 18:10:54 UTC 2023
PRIMARY
All of the following components must be present:
Related Record Type Details
TARGET -> AGONIST
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Definition References